Patents by Inventor Daniel Korr
Daniel Korr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416249Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: May 10, 2023Publication date: December 28, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Ulrich KLAR, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Publication number: 20230064983Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: September 22, 2022Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Publication number: 20220378762Abstract: Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.Type: ApplicationFiled: April 22, 2020Publication date: December 1, 2022Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Franziska SIEGEL, Daniel KORR, Jens SCHRÖDER, Stephan SIEGEL, Heidi GREULICH, Bethany KAPLAN, Matthew MEYERSON
-
Publication number: 20220298157Abstract: Compounds of formula (I), formula (I), processes for their production and their R use as pharmaceuticals.Type: ApplicationFiled: April 22, 2020Publication date: September 22, 2022Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Publication number: 20220226279Abstract: The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R1, R2, R3, R4, R5, R6? Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.Type: ApplicationFiled: April 20, 2020Publication date: July 21, 2022Inventors: Léa Aurelie Bouché, Daniel Korr, Antonius ter Laak, Ernesto Amaury Fernandez-Montalvan, Naomi Barak, Roman Hillig, Roland Neuhaus, Matyas Gorjanacz, Vera Pütter, Stefan Niklaus Gradl, Simon Anthony Herbert, Steven James Ferrara, Craig Strathdee, Jacob Jaffe
-
Patent number: 11339157Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: GrantFiled: October 23, 2018Date of Patent: May 24, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.Inventors: Stephan Siegel, Franziska Siegel, Volker Schulze, Markus Berger, Keith Graham, Ulrich Klar, Knut Eis, Detlev Sülzle, Ulf Bömer, Daniel Korr, Kirstin Petersen, Ursula Mönning, Uwe Eberspächer, Dieter Moosmayer, Matthew Meyerson, Heidi Greulich, Bethany Kaplan, Hassan Youssef Harb, Phi Manh Dinh
-
Publication number: 20200123147Abstract: The present invention provides PRMT5 inhibiting compounds of general formula (I): A compound of general formula (I), in which R1, R2, R3 R4, R5, R6, R7 L1 and L2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 21, 2018Publication date: April 23, 2020Inventors: Lea Aurelie BOUCHE, Duy NGUYEN, Daniel KORR, Marcus KOPPITZ, Antonius TER LAAK, Amaury Ernesto FERNANDEZ-MONTALVAN, Thi Thanh Uyen NGUYEN, Stefan PRECHTL, Andreas JANZER
-
Patent number: 9730929Abstract: The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 30, 2012Date of Patent: August 15, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Patent number: 9284319Abstract: The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: June 21, 2012Date of Patent: March 15, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Publication number: 20150038485Abstract: The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 21, 2012Publication date: February 5, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Publication number: 20140288069Abstract: The present invention relates to amino imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said 10 compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 14, 2012Publication date: September 25, 2014Applicant: Bayer Intellectual Property GmbHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Publication number: 20140194430Abstract: The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 30, 2012Publication date: July 10, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Publication number: 20090029954Abstract: The present invention relates to the single use of the progesterone-receptor antagonist 11?-(4-acetylphenyl)-17?-hydroxy-17?-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof for the prophylaxis and treatment of BRCA1- or BRCA2-mediated breast cancer, as well as to a combination comprising the progesterone-receptor antagonist 11?-(4-acetylphenyl)-17?-hydroxy-17?-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one pure antiestrogen, for the prophylaxis and treatment of BRCA1- or BRCA2-mediated breast cancer, ovarian cancer endometrial cancer, gastric cancer, colorectal cancer, endometriosis, myeloma, myoma and meningioma.Type: ApplicationFiled: April 21, 2008Publication date: January 29, 2009Inventors: Jens HOFFMANN, Daniel Korr
-
Publication number: 20080311594Abstract: The use of fibroblast growth factor Fgf7 and of the corresponding receptor Fgfr2b as biomarker candidates for the progesterone receptor antagonist 11?-(4-acetylphenyl)-17B-hydroxy-17?-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one, also known under the designations ZK230211 or ZK-PRA, of the formula and for antiestrogens is described.Type: ApplicationFiled: June 6, 2008Publication date: December 18, 2008Inventors: Jens Hoffman, Daniel Korr, Jan Kunde, Annete Sommer
-
Publication number: 20080268041Abstract: The present invention relates to the combination of the progesterone-receptor antagonist 11?-(4-acetylphenyl)-17?-hydroxy-17?-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one none-steroidal antiestrogen and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. None-steroidal antiestrogens which can be combined together with the progesterone-receptor antagonist 11?-(4-acetylphenyl)-17?-hydroxy-17?-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one are for example is tamoxifen, raloxifene, droloxifen, toremifen, lasofoxifen, arzoxifen, GW5638, EM-800, idoxifen and basedoxifene.Type: ApplicationFiled: April 18, 2008Publication date: October 30, 2008Inventors: Jens Hoffmann, Daniel Korr
-
Publication number: 20080261933Abstract: The present invention relates to the combination of the progesterone-receptor antagonist 11?-(4-acetylphenyl)-17?-hydroxy-17?-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one lutein-hormone-releasing hormone agonist or antagonist and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Lutein-hormone-releasing hormone agonists and antagonists, which can be combined together with the compound 11?-(4-acetylphenyl)-17?-hydroxy-17?-(1,1,2,2,2 pentafluoroethyl)-estra-4,9-dien-3-one are for example gonadorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histrelin, antide, ramorelix, cetrorelix, antarelix, ORG30850, abarelix, ganirelix and leuprolin.Type: ApplicationFiled: April 21, 2008Publication date: October 23, 2008Inventors: Jens Hoffmann, Daniel Korr
-
Publication number: 20080261929Abstract: The present invention relates to the combination of the progesterone-receptor antagonist 11?-(4-acetylphenyl)-17?-hydroxy-17?-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one aromatase inhibitor and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Aromatase inhibitors which can be combined together with the compound 11?-(4-acetylphenyl)-17?-hydroxy-17?-(1,1,2,2,2 pentafluoroethyl)-estra-4,9-dien-3-one are for example aminoglutethimide, fadrozole, anastrozole, letrozole, vorozole, formestane, exemestane and atamestane.Type: ApplicationFiled: April 18, 2008Publication date: October 23, 2008Inventors: Jens Hoffmann, Daniel Korr